COMPOSITION:
– Each mL contains:
+ Ceftiofur (as hydrochloride) 50 mg
+ Excipients sufficient to 1 mL
DESCRIPTION:
– Cefaject® is a sterile, ready-to-use formulation containing ceftiofur (as hydrochloride), a third-generation beta-lactam cephalosporin antibiotic with a broad spectrum of antibacterial activity; it acts against Gram-positive and Gram-negative bacteria, including beta-lactamase-producing (penicillinase) strains. Like other cephalosporins, ceftiofur has a bactericidal effect, inhibiting the synthesis of the bacterial cell wall.
– Cephalosporins are drugs with a structure similar to penicillin, the basic structure consisting of a cephem nucleus, a fusion of a dihydrothiazine ring (instead of the typical thiazolidine ring of penicillin) and a lactam ring. Variations in the side chains give rise to different cephalosporins, including ceftiofur.
Ceftiofur is rapidly absorbed from the injection site. Therapeutic concentrations are reached within minutes, and peak plasma concentrations are achieved in less than an hour. Its concentration at the site of infection is high, as 90% of the drug binds to tissues and plasma proteins. It acts primarily in the extracellular fluid of the lungs. Furthermore, recent studies demonstrate that the active metabolites of ceftiofur concentrate in tissues and uterine fluid.
It is rapidly metabolized into the main active metabolite desfuroylceftiofur (DFC) and furoic acid. DFC binds to plasma proteins (primarily albumin and alpha-antitrypsin), a reversible binding known as DFC/protein binding. 90% of the drug circulates under these bindings, with 10% remaining unbound to DFC. When proteins at the infection site concentrate, the drug is released. Protein binding provides enhanced transport to the infection site and a longer plasma half-life.
– Excretion occurs in urine (55% in the first 24 hours) and feces (30% in the first 24 hours). Various metabolites are produced in the urine, the main binding substance (87%) being DFC acetamide.
INDICATIONS:
Indicated in cattle, pigs, sheep, goats, and camels, in all infectious processes caused by bacteria susceptible to ceftiofur, including beta-lactamase-producing bacterial strains.
Cattle:
– Treatment and control of respiratory diseases in cattle (BRD: transport fever, bacterial pneumonia) caused by Mannheimia (Pasteurella haemolytica, Pasteurella multocida, and Haemophilus somnus).
– Acute febrile infections in cattle (foot scabies, foot rot, and foot dermatitis) associated with Fusobacterium mortrophorum and Bacteroides melaninogenicus.
– Diarrhea in calves.
– Mastitis: acute and chronic mastitis: Actinomyces pyogenes, Staphylococcus agalactiae, Streptococcus dysgalactiae, Streptococcus uberis, and Streptococcus bovis.
– Eye infections: Conjunctivitis: Moraxella bovis.
– Genital tract infections: puerperal fever, acute and chronic endometritis between 0-14 days postpartum associated with Arcanobacterium pyogenes, alone or in combination with Fusobacterium mortrophorum and Bacteroides spp. Actinobacillus (Haemophilus) pleuropneumoniae, P. multocida, Salmonella choleraesuis, and Escherichia coli.
– Clostridial diseases: Clostridium chauvoei, C. osystem, C. novyi, C. perfringens, C. sordellii, C. botulinum, C. haemolyticum.
Pig:
– Treatment and control of respiratory diseases in pigs (bacterial pneumonia in pigs) associated with Actinobacillus (Haemophilus) pleuropneumoniae, Pasteurella multocida, Salmonella choleraesuis, Haemophilus parasuis, Streptococcus suis, and Streptococcus suis type II.
– Joint infections: septicemia, polyarthritis, polyserositis. Streptococcus suis and Haemophilus parasuis.
– Uterine infections: MMA syndrome (mastitis, endometritis, and mastitis), Streptococcus suis, Streptococcus spp., and Escherichia coli.
Sheep, goats, and camels:
– Treatment of respiratory tract infections (pneumonia) caused by Mannheimia (Pasteurella) haemolytica, Pasteurella multocida, and Proteus mirabilis.
Susceptible bacteria:
– Gram-negative bacteria:
Pasteurella haemolytica (Mannheimia spp.), Pasteurella multocida, Haemophilus somnus, Fusobacterium mortrophorum, Bacteroides fragilis group, Bacteroides spp. (nofragilis group), Actinobacillus (Haemophilus) pleuropneumoniae, Moraxella bovis, Salmonella spp., Haemophilus parasuis, Actinobacillus suis, Arcanobacterium pyogenes, and Escherichia coli.
– Gram-positive:
Staphylococcus hyicus, Streptococcus suis, Peptostreptococcus anaerobes, Streptococcus spp. Beta-hemolytic.
INSTRUCTIONS FOR USE AND DOSAGE:
– Deep intramuscular or subcutaneous injection.
Cattle:
Intramuscular injection at a dose of 1–2.2 mL per 50 kg body weight (1–2.2 mg ceftiofur per kg body weight). Treatment should be repeated at 24-hour intervals for 3 consecutive days (up to 5 days in case of endometritis).
Spigs:
Intramuscular injection at a dose of 0.6–1 mL per 10 kg body weight (3–5 mg ceftiofur per kg body weight). The treatment must be repeated every 24 hours for 3 consecutive days (up to 5 days in the case of endometritis).
Sheep, goats, and camels:
– Treatment of respiratory tract infections (pneumonia) caused by Mannheimia (Pasteurella) haemolytica, Pasteurella multocida, and Proteus mirabilis.
Susceptible bacteria:
– Gram-negative:
Pasteurella haemolytica (Mannheimia spp.), Pasteurella multocida, Haemophilus somnus, Fusobacterium mortrophorum, Bacteroides fragilis group, Bacteroides spp. (nofragilis group), Actinobacillus (Haemophilus) pleuropneumoniae, Moraxella bovis, Salmonella spp., Haemophilus parasuis, Actinobacillus suis, Arcanobacterium pyogenes, and Escherichia coli.
– Gram-positive:
Staphylococcus hyicus, Streptococcus suis, Peptostreptococcus anaerobes, and Streptococcus spp. Beta-hemolytic.
INSTRUCTIONS FOR USE AND DOSAGE:
– Administer by deep intramuscular or subcutaneous injection.
Cattle:
Intramuscular injection at a dose of 1–2.2 mL per 50 kg body weight (1–2.2 mg ceftiofur per kg body weight). Treatment should be repeated at 24-hour intervals for 3 consecutive days (maximum 5 days in case of endometritis).
Sows:
Intramuscular injection at a dose of 0.6–1 mL per 10 kg body weight (3–5 mg ceftiofur per kg body weight). Treatment should be repeated every 24 hours for 3 consecutive days (maximum 5 days in case of endometritis).
Sheep, goats, and camels:
Intramuscular injection of 0.22–0.44 mL (1.1–2.2 mg Ceftiofur) per 10 kg body weight every 24 hours for 3 consecutive days. Further treatment should be repeated for 4 to 5 days for animals that do not respond well.
PACKAGING: 100 ml bottle
